Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBITDA Margin for 9 consecutive years, with 765.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 54302.0% to 765.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 72.11% through Dec 2025, down 4189.0% year-over-year, with the annual reading at 72.11% for FY2025, 3808.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 765.68% at Marker Therapeutics, up from 173.3% in the prior quarter.
  • The five-year high for EBITDA Margin was 823.03% in Q4 2023, with the low at 1320.14% in Q1 2025.
  • Average EBITDA Margin over 4 years is 242.49%, with a median of 189.1% recorded in 2024.
  • The sharpest move saw EBITDA Margin skyrocketed 148835bps in 2023, then tumbled -111525bps in 2025.
  • Over 4 years, EBITDA Margin stood at 400.28% in 2022, then surged by 306bps to 823.03% in 2023, then crashed by -73bps to 222.66% in 2024, then skyrocketed by 244bps to 765.68% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 765.68%, 173.3%, and 494.79% for Q4 2025, Q3 2025, and Q2 2025 respectively.